NMAD earnings analysis
What we found in NMAD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include income statement, balance sheet, cash flow, or segment results, so revenue, margins, EPS, liquidity, and cash-burn trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material changes to the risk factors disclosed in the December 31, 2025 Form 10-K. The merger agreement dated June 11, 2026 and amended June 30, 2026 is the principal corporate development disclosed in the provided text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Deemed Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was reported on time.
- Merger Transaction Progresses
- The company filed a merger agreement dated June 11, 2026, involving Lixte Biotechnology Holdings, NBD Merger Sub, and NOMAD Transportable Power Systems; Amendment No. 1 was dated June 30, 2026.
- No Insider Trading Plans Changed
- No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the six months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Legacy 2025 Risks Remain Material
- The company states that the risk factors in its 2025 Form 10-K, covering the fiscal year ended December 31, 2025, could materially adversely affect its business, financial condition, results, and cash flows. No material changes to those risks were identified as of the August 14, 2026 filing date.
- Merger Execution Uncertainty
- The merger agreement dated June 11, 2026 was amended on June 30, 2026, indicating that the transaction remains subject to amendment-related execution and closing uncertainty.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text; outlook appears deferred to an earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 31, 2026
- Lixte Biotechnology Holdings, Inc. reported a significant net loss of $6.01 million for the year ended December 31, 2025, primarily driven by increased operating expenses, particularly in general and administrative…
- 10-Q · November 12, 2025
- Lixte Biotechnology Holdings, Inc. reported a net loss of $3.47 million for the nine months ending September 30, 2025, widening from a loss of $2.97 million in the prior year. The company continues to show no revenue…
- 10-Q · August 7, 2025
- Lixte Biotechnology Holdings, Inc. reported no revenues for the second quarter of 2025, maintaining consistent operational losses amidst ongoing drug development efforts. Notable reductions in operating expenses were…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NMAD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever